BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that management will
present at the following healthcare-focused investment banking
conferences in November 2017:
Credit Suisse 26th Annual Healthcare Conference
November 8, 2017 at
12:20 pm MT
To view the webcast follow
this link: INVA
at Credit Suisse
Stifel Nicolaus Weisel 2017 Healthcare Conference
November 15, 2017
at 10:15 a.m. ET
New York, NY
To view the webcast follow this
Both presentations will be available and archived on the investor
relations page of the Innoviva web site at: http://investor.inva.com/events.cfm.
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA®, ANORO® ELLIPTA® and TRELEGY ELLIPTA®, which were jointly
developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is
eligible to receive associated royalty revenues from RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent
economic interest in future payments made by GSK for TRELEGY® ELLIPTA®
and earlier-stage programs partnered with Theravance BioPharma, Inc..
For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005238/en/
Senior Vice President and Chief
Source: Innoviva, Inc.
News Provided by Acquire Media